Langenbach, Isabel L. http://orcid.org/0000-0001-7410-0635
Langenbach, Marcel C.
Mayrhofer, Thomas
Foldyna, Borek
Maintz, David
Klein, Konstantin
Wienemann, Hendrik
Krug, Kathrin B.
Hellmich, Martin
Adam, Matti
Naehle, Claas P.
Funding for this research was provided by:
Universitätsklinikum Köln
Article History
Received: 16 July 2023
Revised: 25 August 2023
Accepted: 17 September 2023
First Online: 18 November 2023
Declarations
:
: The scientific guarantor of this publication is Marcel C. Langenbach, MD.
: The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.The authors of this manuscript declare relationships with the following companies:Hendrik Wienemann has received institutional grant support from Abbott Vascular.Borek Foldyna has received unrelated research grants from the NHI/NHLBI, AstraZeneca, Eli Lilly, and MedTrace.All other authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: Thomas Mayrhofer and Martin Hellmich kindly provided statistical advice for the manuscript.
: Written informed consent was obtained from all patients in this study.
: Institutional Review Board approval was obtained. The HIPAA-compliant study protocol was approved by the local institutional review board (IRB) (IRB No. 21-1245, German clinical trials register DRKS00025702) as a quality assurance trial. Written informed consent was obtained before inclusion. Patients were consecutively enrolled for this prospective study between June 2021 and November 2021.
: No study subjects have been previously reported.
: • prospective• experimental Study• performed at one institution